Andrew McConaghie
Senior Writer
Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
CureVac Could Be Third mRNA Vaccine Approval – But With A ‘Europe First’ Approach
Caught in a ‘vaccine nationalism’ crossfire a year ago, CureVac is now well placed to become a commercial entity – just as long as its mRNA platform can deliver.
After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino On Possible ‘Class Effect’
Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.
After J&J Vaccine Pause, Urgent Safety Questions for Sputnik And CanSino
Potentially fatal blood clots seen in AZ and J&J’s COVID-19 vaccine could be common to all adenovirus vector vaccines – but Russia and China developers are dismissing a possible link.
Vaccitech Prepares For IPO, But AZ COVID-19 Vaccine Safety Fears Cloud Launch
The UK biotech aims to raise $100m, but will need to tackle safety concerns to secure a long-term future.
Sanofi Adds mRNA Specialist Tidal To Acquisition Spree
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
AZ’s ‘Long Shot’ COVID-19 Trial Of Diabetes Drug Farxiga Fails
The failure of the SGLT2 inhibitor is not unexpected, but allays any concerns that it could have worsened outcomes for patients with hypertension or heart disease.